Non-vitamin K antagonist oral anticoagulants (NOACs) reduce the risk of thromboembolism
in patients with atrial fibrillation (AF). There has been no head-to-head comparison of the …

Non-vitamin K antagonist oral anticoagulants (NOACs) are replacing warfarin and heparins
in several clinical situations. With varying modes of action, the effects of NOACs on thrombus …

Background Although patients taking non-vitamin K antagonist oral anticoagulants (NOACs)
do not require routine coagulation monitoring, high-risk patients require monitoring to …

Abstract Background Direct oral anticoagulants (DOACs) are known to prevent thrombosis
but there is limited information about their activity on the clot formation and lysis cascade …

Importance The non–vitamin K antagonist oral anticoagulants (NOACs) apixaban,
dabigatran, edoxaban, and rivaroxaban are administered in fixed doses without …

Prevention of thromboembolism is the key priority in the management of patients with atrial
fibrillation (AF). Clinical decisions on antithrombotic management should be based on the …

Background Current guidelines recommend vitamin K antagonists (VKAs) or non-vitamin K
antagonist oral anticoagulants (NOACs) for stroke prevention in patients with non-valvular …

In patients with non-valvular atrial fibrillation (NVAF), oral anticoagulation is important for
prevention of stroke and systemic embolism (SE). While Vitamin K antagonists (VKAs) have …

Background The nonvitamin K antagonist oral anticoagulants have recently become
available as an alternative to warfarin as stroke prophylaxis in atrial fibrillation, but data on …

Aims: Thrombocytopenia was one of the exclusion criteria in randomized trials in which non–
vitamin K antagonist oral anticoagulants (NOACs) were tested. The safety of NOACs in …